期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

玻璃体腔注射抗血管内皮生长因子单克隆抗体Bevacizumab治疗糖尿病性黄斑水肿的护理

下载PDF
导出
摘要 糖尿病性黄斑水肿（DME）是导致糖尿病视网膜病变（diabetic retinopathy ，DR）患者视力受损的主要原因之一，既往主要的治疗方法是采用视网膜光凝封闭渗漏的微血管瘤和毛细血管。黄斑区格栅样光凝对部分黄斑水肿有较好疗效［1］，但是弥漫性黄斑水肿仍有24％的患者对激光光凝治疗不敏感［2］。血管内皮生长因子（VEGF）引起的视网膜血管渗漏增加是导致黄斑水肿的关键［3］；所以抗VEGF单克隆抗体Bevacizumab （即 Avastin）在治疗该病方面颇受青睐，且取得了令人鼓舞的效果［3‐5］。我们采用玻璃体腔内注射Bevacizumab的方法，治疗了一组DM E患者，取得较好疗效，现将护理结果汇报如下。
作者 杜巧芳
机构地区 山东医学高等专科学校附属眼科医院
出处 《山东医学高等专科学校学报》 2015年第4期279-280,共2页 Journal of Shandong Medical College
关键词 血管内皮生长因子:糖尿病 黄斑水肿 玻璃体腔
分类号 R473.7 [医药卫生—护理学]
  • 相关文献

参考文献6

  • 1Photocoagulation for diabetic macular edema. Early treatment dia-betic retinopathy study report number 1: early treatment diabeticretinopathy study research group[]-. Arch Ophthalmol, 1995, 103:1796-1806.
  • 2Lee CM, Olk RJ. Modified grid laser photocoagulation for diffusediabetic macular edema: long-term visual results[J]. Ophthalmology,1991, 98: 1594-1602.
  • 3Tolentino MJ, Miller JW, Gragoudas ES, et al. Intra- vitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an a- dult primate[J-. Ophthalmology, 1996, 106: 1820- 1828.
  • 4Avery RL, Pieramici DJ, Rabena MD, et al. Intravit- real Bevacizumab (Avastin) for neovaseular age-relat- ed macular degeneration [J]. Ophthalmology, 2006, 113..363-372.
  • 5Iterralde D, Spaide RF, Meyerle CB, et al. Intravit- real Bevacizumab (Avastin)treatment of macular ede- ma in central retinal vein occlusion., a short-term study[J]. Retina, 2006,26 .. 279-284.
  • 6胡洁,唐仕波,梁小玲,胡忆群,文峰,邵娟,刘清云.玻璃体腔单次注射抗血管内皮生长因子单克隆抗体Bevacizumab治疗糖尿病性黄斑水肿[J].中华眼底病杂志,2008,24(3):172-175. 被引量：9

二级参考文献13

  • 1Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology, 2003, 110 : 1677- 1682.
  • 2Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol, 1985,103 : 1796-806.
  • 3Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology, 2002, 109: 920-927.
  • 4Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol, 2003, 121: 57-61.
  • 5Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravifreal injections of vascular endothelial growth factor produce retinal isehemia and mieroangiopathy in an adult primate. Ophthalmology, 1996, 106:1820-1828.
  • 6Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 2006,113 : 363-372.
  • 7Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion : a short-term study. Retina, 2006,26 : 279- 284.
  • 8Arevalo F J, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal Bevacizumab (Avastin) for diabetic macular edema- results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up. Ophthalmology, 2007, 114:743-750.
  • 9Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 2004,25 : 581-611.
  • 10Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology, 2006, 113:294-301.

共引文献8

山东医学高等专科学校学报
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部